Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) confirmed by a tissue sample, by standard liver cancer diagnostic guidelines, or as a recurrence after surgery
- People between 18 and 75 years of age
- People whose liver cancer is classified as middle stage (Stage B) or late stage (Stage C) according to a standard liver cancer staging system called BCLC
- People who have received certain liver-directed treatments (such as TACE or HAIC), either combined with specific medicines (Bevacizumab and a PD1/L1 inhibitor) as a first treatment, or who have previously tried other systemic treatments but could not tolerate them or whose cancer stopped responding
- People whose liver function falls within a certain acceptable range, classified as Child-Pugh class A or B (a measure of liver health)
- People who are reasonably physically functional, with a performance score of 0, 1, or 2 on a standard scale (meaning able to carry out daily activities with little to no limitation)
- People whose blood test results meet specific thresholds for red blood cells, liver enzymes, kidney function, and blood clotting (confirm specific values with trial site)
- People who are able to understand the trial procedures and are willing to sign a consent form
Who may not be able to join:
- People whose liver cancer is a type called cholangiocarcinoma (a different kind of liver cancer)
- People for whom relevant medical imaging is not available
- People whose expected survival is less than 3 months
- People with serious other medical conditions
- People showing signs that the liver is no longer functioning adequately, such as fluid build-up in the abdomen, gastrointestinal bleeding, or confusion caused by liver failure
- People with a known history of HIV
- People who have previously received an organ transplant
- People with a known or suspected allergy to any of the medicines used in this trial
- People with certain serious heart rhythm problems that require medication to control
- People with evidence of a condition that causes abnormal or uncontrolled bleeding
- People who have had a significant gastrointestinal bleed within the 30 days before joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Feng duan, MD, Chinese PLA General Hospital
Phone: 86 19868000115
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-Free-Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.